For a special limited time:

         Save 30%!

 Get all 3:


  for one low price.

                Learn more

Pharmacyclics Alert

publication date: Mar 5, 2015

Perhaps this is more of congratulations to our subscribers than it is an alert.  The announcement that AbbVie is stepping up to pay $21 billion for portfolio stock Pharmacyclics (PCYC) has sent the stock above the $250 level.  Not bad for a stock we introduced to you in the portfolio at $5 bucks.

The deal also puts to bed any significant competition concerns from AbbVie’s ABT-199.

The sharp move higher in the stock will bolster our phenomenal +50% gain already achieved in 2015 in the Cell Signaling and Cancer Stem Cells portfolio.

Thanks for all the calls to us as we really “appreciate the appreciation” if you will, but if you could hold off on calling and email a testimonial that would also be appreciated as right now  we are in the middle of an order taking exercise with lots of new subscribers. 

Congratulations TRIUMPH investors!  We’ll have more on the news shortly as well as thoughts on the portfolio not so suddenly swelled with huge profits from this stock.


Rick Currin